Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Metadata
Title
Targeting STAT3 affects melanoma on multiple fronts
Authors
Marcin Kortylewski
Richard Jove
Hua Yu
Publication date
01-06-2005
Publisher
Kluwer Academic Publishers
Published in
Cancer and Metastasis Reviews / Issue 2/2005
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-005-1580-1

Other articles of this Issue 2/2005

Cancer and Metastasis Reviews 2/2005 Go to the issue

OriginalPaper

Guest Editor

OriginalPaper

Role of nuclear factor-κ B in melanoma

OriginalPaper

Introduction

OriginalPaper

Protein kinase C in melanoma

OriginalPaper

Immunological detection of altered signaling molecules involved in melanoma development

OriginalPaper

Integrin signaling in malignant melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits